Bank of New York Mellon Corp Increases Stock Holdings in Applied Therapeutics Inc. (NASDAQ:APLT)

Bank of New York Mellon Corp boosted its position in shares of Applied Therapeutics Inc. (NASDAQ:APLT) by 23.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 316,455 shares of the company’s stock after acquiring an additional 59,178 shares during the quarter. Bank of New York Mellon Corp owned 0.22% of Applied Therapeutics worth $155,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of APLT. Ground Swell Capital LLC acquired a new stake in Applied Therapeutics in the 4th quarter valued at about $27,000. Toronto Dominion Bank acquired a new stake in shares of Applied Therapeutics during the 4th quarter worth about $27,000. Dark Forest Capital Management LP raised its position in shares of Applied Therapeutics by 54.5% during the 4th quarter. Dark Forest Capital Management LP now owns 53,718 shares of the company’s stock worth $46,000 after acquiring an additional 18,949 shares in the last quarter. Tudor Investment Corp ET AL acquired a new stake in shares of Applied Therapeutics during the 4th quarter worth about $49,000. Finally, California State Teachers Retirement System raised its position in shares of Applied Therapeutics by 923.3% during the 4th quarter. California State Teachers Retirement System now owns 71,282 shares of the company’s stock worth $61,000 after acquiring an additional 64,316 shares in the last quarter. 98.31% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $1.50 price target on shares of Applied Therapeutics in a research report on Wednesday, May 14th. Wall Street Zen raised Applied Therapeutics to a “sell” rating in a research report on Saturday, July 26th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $6.10.

Applied Therapeutics Price Performance

Shares of NASDAQ:APLT opened at $0.48 on Wednesday. The firm has a market capitalization of $67.32 million, a PE ratio of -1.11 and a beta of 1.97. The business has a 50-day moving average of $0.39 and a two-hundred day moving average of $0.45. Applied Therapeutics Inc. has a 12 month low of $0.30 and a 12 month high of $10.62.

Applied Therapeutics Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.